Copy
Problems viewing this newsletter? View it in your browser >



September 11, 2012

Dear Advocate,

This message includes information on two upcoming webinars that will provide updates on the state of the rapidly evolving PrEP field. The first will be held on September 18th and will describe the content and implications of recent regulatory developments including the US Food and Drug Administration approval of daily TDF/FTC as PrEP and the guidelines from World Health Organization and various countries. The October 3rd webinar will review ongoing and planned oral PrEP research that goes beyond daily oral TDF/FTC. Both calls will provide ample time for questions, answers and discussions—we hope you’ll join us.

New Guidance on Daily Oral PrEP: What’s out there and what does it mean for advocates?
On Tuesday, September 18th from 11am–noon US Eastern (to check the time in your area please visit www.timeanddate.com), representatives from the US Food and Drug Administration, the US Centers for Disease Control and Prevention, the World Health Organization, the Southern African HIV Clinicians Society, the British HIV Association and the British Association for Sexual Health and Gilead Sciences will discuss various guidelines on the use of and FDA approval of daily TDF/FTC as PrEP. This webinar will familiarize advocates with the types of regulatory and normative guidance documents that exist on PrEP—what they say, who they affect and what they may mean for policy and programming in various countries.

Register here.

Beyond Daily TDF/FTC as PrEP: Exploring new drugs and regimens for PrEP
On Wednesday, October 3rd from 10–11am US Eastern (check the time in your area at www.timeanddate.com), PrEP researchers will discuss ongoing trials of new oral PrEP interventions, including non-daily regimens (also described as “intermittent PrEP”) and new drugs such as maraviroc. Joining us will be principal investigators Bob Grant (ADAPT), Trip Gulick (NEXT-PrEP), Sheena McCormack (PROUD) and Jean-Michel Molina (ANRS Ipergay). These trials all seek to answer questions about strategies other than daily oral TDF/FTC and will provide important information on potential “second generation” oral PrEP.

Register here.

For a complete, updated list of PrEP research and other HIV prevention trials, visit our HIV Prevention Research + Development Database at www.avac.org/pxrd.

We hope that you will join both of these webinars, which will be recorded, and we welcome any advance questions at avac@avac.org. Additional background on PrEP can be found at www.avac.org/prevention-option/prep.

Best,
AVAC






Forward This IssueDo you know someone who might be interested in receiving this newsletter?
Forward > 


Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
Unsubscribe > 


Contact Us T: +1 212 796 6423
E: avac@avac.org

W: www.avac.org